在败血症免疫微环境中识别和实验验证cuproptosis调节程序,通过单细胞和散装RNA测序的组合进行测序
Tingru Zhao1, Yan Guo1, Jin Li1
1Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Frontiers in immunology
|July 1, 2024
概括
这项研究开发了一种使用cuproptosis (细胞死亡过程) 预测患者结果的败血症风险模型. 这项研究确定了包括LST1在内的关键基因,为败血症治疗提供了新的目标.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 尽管死亡率高,但败血症的发病因子仍然不完全理解.
- 质亡,一种新的细胞死亡途径,与败血症有关.
- 针对性治疗败血症需要更好地了解其潜在机制.
研究的目的:
- 建立基于cuproptosis的风险模型来诊断和预测败血症风险.
- 为潜在的向性败血症疗法确定与cuproptosis相关的基因 (CRG).
- 研究特定的CRG,如LST1,在败血症病理生理学的作用.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 用于分析cuproptosis活动评分 (CuAS) 和细胞间通信.
- 使用scRNA-seq和大量RNA测序识别差异表达的CRG.
- 使用LASSO和考克斯回归分析开发风险预测模型.
- 在三个外部队列中验证风险模型.
- 评估免疫细胞透,通路丰富和免疫调节器的表达.
- 在体外实验 (流细胞测量,西部斑块,ELISA) 来研究LST1.1.的功能.
主要成果:
- CuAS富含单细胞,与败血症预后不佳相关.
- 较高的CuAS与细胞间相互作用的增加有关.
- 建立了一个五个CRG风险模型,准确预测败血症预后.
- 较低风险得分队列显示免疫细胞透和抗菌反应的增强.
- 一个关键的基因LST1在LPS刺激后在巨细胞中升高调节,从而降低了生存率,并促进了亡和氧化应激.
结论:
- 一个新的cuproptosis相关的风险模型有效地预测了败血症的预后.
- 这项研究确定了LST1作为在败血症中关键的cuproptosis相关基因.
- 这些发现为开发向性败血症治疗提供了理论基础.
相关概念视频
01:30Pulse rhythm
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
01:29Disturbances in Heart Rhythm
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:23Holter Monitor: 24-Hour Monitoring
Holter monitoring is a continuous electrocardiography (ECG) recording that tracks the heart's electrical activity over an extended period, generally 24 to 48 hours. This noninvasive diagnostic tool detects irregular heart rhythms that may not be captured during a standard ECG performed in a clinical setting.DeviceThe Holter monitor is a portable, small device connected to several electrodes on the patient's chest. These electrodes detect the heart's electrical signals and transmit them to the...
01:18Dysrhythmias IV: Characteristics of Bradyarrhythmias
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
01:30Dysrhythmias V: Evaluating Dysrhythmias
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...